Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Advanced Cancer × Trastuzumab × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 250 Stomach Neoplasms 27 Neoplasm Metastasis 21 Neoplasms 15 Colorectal Neoplasms 13 Breast Neoplasms, Male 13 HER2-positive Breast Cancer 11 Triple Negative Breast Neoplasms 8 Esophageal Neoplasms 8 Inflammatory Breast Neoplasms 7 Rectal Neoplasms 6 Brain Neoplasms 6 Adenocarcinoma 6 Pathologic Complete Response 5 Colonic Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Salivary Gland Neoplasms 4 Gallbladder Neoplasms 4 Biliary Tract Neoplasms 4 Urologic Neoplasms 3 Urinary Bladder Neoplasms 3 Recurrence 3 Cholangiocarcinoma 3 Carcinoma, Ductal, Breast 3 Sarcoma 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Osteosarcoma 2 Neoplastic Cells, Circulating 2 Multiple Myeloma 2

Interventions

relatlimab 2 linrodostat 2 Nivolumab 2 Ipilimumab 2 Vorinostat 1 Trastuzumab 1 IFL protocol 1 Gemcitabine 1 Dasatinib 1 Cetuximab 1 BMS-813160 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05605509 2026-02-06

RP-6306 in Patients With Advanced Cancer

Canadian Cancer Trials Group

Phase 2 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡